J Korean Pediatr Soc Search

CLOSE


Journal of the Korean Pediatric Society 1995;38(10):1384-1393.
Effect of Prophylactic Treatment of High Doses Recombinant Human Erythropoietin on Anemia in Premature Infants
Soon Seong Park, Seong Ho Hong, Hye Lime Jung, Dong Hyeok Keum
Department of Pediatrics, Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Korea
고용량의 유전자 재조합형 인성 Erythropoietin의 미숙아 빈혈에 대한 예방효과
박순성, 홍성호, 정혜림, 금동혁
삼성의료원 강북상섬병원 소아과
Abstract
Purpose
: This study was conducted to determine whether prophylatic treatment with recombinant human erythropoietin(rHuEPO) could prevent anemia and reduce the need for blood transfusion in premature infants.
Methods
: This study was conducted from May, 1992 to July 1994. We randomly assigned 24 premature infants with gestational age less than 34 weeks and birth weight less than 2.0kg. After having assigned 13 infants into treatment group and 11 infants into control group, rHuEPO was administered intravenously or subcutaneously three times a week to 13 treatment infants at dose of 12ooIU/kg per week for 4 weeks, starting at second day of life. We have checked hemoglobin, hematocrit, reticulocyte, setum ferritin, serum erythropoietin in both control and treatment group at the time of the birth and weekly for 4 weeks after birth.
Results
: The two groups had similar birth weights and clinical variables. During the 4 weeks of observation, the treated infants required fewer blood transfusion(0.3¡¾0.6 vs 1.0¡¾1.3 : p<0.05). Hemoglobin and hematocrit values were higher in the treated group(12.1¡¾1.3% vs 10.5¡¾1.2% ; p<0.05 and 38.2¡¾4.8% vs 31.5¡¾4.2% ; p<0.05). Reticulocyte and serum erythropoietin values were higher in the treated group(5.7¡¾3.2% vs 1.7¡¾ 0.7% ; p<0.05 and 132.47mU/ml¡¾ 96.18mU/ml¡¾96.18mU/ml vs 5.66mU/ml¡¾3.27mU/ml ; p<0.05). No prominent adverse effects of intravenously or subcutaneously administered rHuEPO were noted.
Conclusion
: Our data indicate that prophylactic administration of high dose rHuEPO is safe and effective in stimulating erythropoiesis and reducing the requirement for blood transfusions in premature infants.
Key Words: rythropoiethin, Premature infant, Transfusion


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
#1606 Seocho World Officetel, 19 Seoun-ro, Seocho-ku, Seoul 06732, Korea
Tel: +82-2-3473-7305    Fax: +82-2-3473-7307    E-mail: kjpped@gmail.com                

Copyright © 2018 by Korean Pediatric Society. All rights reserved.

Developed in M2community

Close layer
prev next